Edgewise Therapeutics, Inc. (EWTX)
Nasdaq: EWTX · Pharmaceutical Preparations · Boulder, CO · filing with the SEC since 2019
Who owns Edgewise Therapeutics, Inc.
As filed with the SECHolders of 5% or more
6
Orbimed Advisors LLC holds 14.5% of Common Stock, as its SCHEDULE 13D/A filed May 12, 2025 says.
Directors and officers
15
report now, of 20 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
Orbimed Advisors LLC
SCHEDULE 13D/A · filed May 12, 2025 · Common Stock
Paradigm BioCapital Advisors LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.0001 par value per share · 6.2% in Feb 17, 2026
RA Capital Management, L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share · 9.9% in Nov 14, 2025
Janus Henderson Group PLC
SCHEDULE 13G · filed May 15, 2026 · Common Stock · 4.7% in Nov 14, 2025
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 17, 2025 · Common Stock
Fmr LLC
SCHEDULE 13G · filed Aug 6, 2026 · COMMON STOCK
Novo Holdings A/S
SCHEDULE 13D/A · filed Apr 27, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%
Perceptive Advisors LLC
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 6.1% in May 15, 2025
Baker Bros. Advisors LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 6.9% in Aug 14, 2025
What EWTX reports owning in othersstakes of 5% or more, and other ties
Edgewise Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
34sales
1purchases
11sales on a scheduled plan
7people selling
$19.7Msold, in dollars
$200,000bought, in dollars
Open-market trades on Form 4 from Nov 10, 2025 to Nov 10, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 10, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window8 of 26 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Russell Alan J | Chief Scientific Officer | 6 | $10.3M | 2 | 0 | $0 |
| Donovan Joanne M. | CMO | 11 | $4.6M | 4 | 0 | $0 |
| Edris Badreddin | director | 5 | $3.4M | 5 | 0 | $0 |
| Koch Kevin | President and CEO | 3 | $800,000 | 0 | 0 | $0 |
| Nofi Michael | Chief Financial Officer | 1 | $200,000 | 0 | 0 | $0 |
| Derakhshan Behrad | Chief Business Officer | 4 | $200,000 | 0 | 0 | $0 |
| Moore John R | General Counsel | 4 | $200,000 | 0 | 0 | $0 |
| Fox Jonathan C | director | 0 | $0 | 0 | 1 | $200,000 |